Results 191 to 200 of about 43,463 (255)

Progression to Dementia in Very Late‐Onset Schizophrenia‐Like Psychosis Stratified by Alzheimer's Disease and Lewy Body Disease Biomarkers: A Retrospective Cohort Study

Psychogeriatrics, Volume 26, Issue 5, September 2026.
ABSTRACT Background Very late‐onset schizophrenia‐like psychosis (VLOSLP) is clinically heterogeneous, and its relationship with dementia‐related neurodegenerative disease remains unresolved. We examined whether Alzheimer's disease (AD) and Lewy body disease (LBD) biomarker status were associated with dementia progression in VLOSLP.
Yuto Satake, Hideki Kanemoto, Daiki Taomoto, Kayo Takeda, Shigeki Katakami, Matasaburo Kobayashi, Keiko Matsunaga, Kayako Isohashi, Takashi Suehiro, Kenji Yoshiyama, Manabu Ikeda   +10 more
wiley   +1 more source

Thermo‐Mechanical Topology Optimization: An Immersed FEM Level‐Set‐Based Approach

International Journal for Numerical Methods in Engineering, Volume 127, Issue 15, 15 August 2026.
ABSTRACT This paper proposes a multi‐physics framework for topology optimization using an immersed level set‐finite element model. The work extends the capabilities of a recently developed immersed level‐set method to thermo‐mechanical problems, including coupling and material‐dependent properties.
Farzad Tatar, Silvia Monchetti, Elisabetta Manconi, Roberto Brighenti   +3 more
wiley   +1 more source

EEG network reorganization across Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies. [PDF]

Alzheimers Dement (Amst)
Benussi A, Cantoni V, Palacino F, Altomare D, Moretti DV, Manganotti P, Borroni B.   +6 more
europepmc   +1 more source

Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
We present a set of multifunctional tacrine derivatives, designed with the CADMA‐Chem protocol, aimed for Alzheimer and Parkinson diseases. Of the tacrines designed, TAC‐674 and TAC‐678 are the best candidates to act as multifunctional antioxidants and neuroprotectors for Alzheimer and Parkinson diseases, respectively.
Eugenia Dzib, Luis Felipe Hernández‐Ayala, Silvana Silva‐Aguirre, Annia Galano   +3 more
wiley   +1 more source

Discriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer's Disease: A Targeted Mass Spectrometry and Machine Learning Approach. [PDF]

Neuropsychiatr Dis Treat
Wen L, Zhang Y, Nie Y, Shen H, Qin Q, Qu M.   +5 more
europepmc   +1 more source

Large‐scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation

FEBS Open Bio, Volume 16, Issue 8, Page 1563-1592, August 2026.
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane, Lea Nikolić, Lorenzo Maraio, Thomas Goiran, Nathan Karpilovsky, Stefano Sellitto, Vangelis Bouris, Jiang‐An Yin, Ronald Melki, Edward A Fon, Adriano Aguzzi, Elena De Cecco   +11 more
wiley   +1 more source

Alpha-synuclein seeding activity in postmortem tissues from patients with diffuse and isolated Lewy bodies. [PDF]

Acta Neuropathol Commun
Baranová S, Matěj R, Soukup J, Dušek P, Holada K.   +4 more
europepmc   +1 more source